Chief Executive Officer
Didier Laurens has extensive experience in the finance and healthcare sectors where he has served as CFO and financial analyst specializing in the pharma/biotech sector. He was previously CFO of Ecential Robotics, a private medical technology company, which markets robotic solutions for spine surgery.
Didier was previously CFO of Pixium Vision (Euronext Paris: ALPIX), interim CFO of Korian (Euronext Paris: KORI) after having been its Director of Financing, Treasury and Investor Relations.
From 1999 to 2013, Didier was a financial analyst specialized in the healthcare sector at Oddo BHF and Société Générale. He also managed the mid-cap equity research of these two banks and participated in numerous IPOs in the healthcare sector.
Didier holds a Pharm D. in pharmacy (Paris V), a post-graduate diploma in galenic pharmacy and is a graduate of the French Society of Financial Analysts (CIIA / SFAF), of which he was one of the directors.
André Ulmann, MD, PhD
André Ulmann’s career spans some thirty years in research and the pharmaceutical industry, as well as in medical practice. He serves as an active advisor to Advicenne from conception through drug development.
André is currently a Director of HRA Pharma, which he founded and managed until 2009 before assuming the presidency. In 1999, HRA Pharma launched Norlevo, better known as the “morning-after pill.” Norlevo is now available in more than fifty countries and has made HRA Pharma a pioneer in emergency contraception. Under André’s leadership, HRA Pharma has become a socially-conscious pharmaceutical company that designs and develops medical products and devices for the treatment of rare diseases and unmet medical needs.
André is a MD, and began his career practicing Nephrology at Hôpital Necker (Paris, France).
Catherine Guittet, PharmD
Head of Clinical Operations Department
Catherine Guittet joined Advicenne in 2008 and is responsible for clinical research, regulatory affairs and project management. With over fifteen years of experience in clinical affairs and regulatory matters, Catherine has held positions with Merck Serono, where she managed a unit dedicated to the coordination of early clinical development in oncology, as well as with the French biotech company, Synt:em. For several years, she served as Head of the Patient Clinical Study Unit at SGS-Aster (a contract research organization). Catherine began her career as Head of Project Management at Theraplix (Sanofi-Aventis).
Catherine received her Doctor of Pharmacy (PharmD) and PhD from Angers University, graduated as Clinical Investigator from Paris VII University, obtained a Pharmaco-Epidemiology Certificate from Bordeaux II University, as well as a Cellular Pharmacology, Pharmacogenetics and Pharmacokinetics Certificate from Paris VII University.
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2020 Advicenne